Bristol-Myers Squibb and AstraZeneca complete expansion of diabetes alliance
17:00 EDT 9 Aug 2012 | World Pharma News
Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca (LSE:AZN) announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 b..
Original Article: Bristol-Myers Squibb and AstraZeneca complete expansion of diabetes alliance
More From BioPortfolio on "Bristol-Myers Squibb and AstraZeneca complete expansion of diabetes alliance"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
